BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

795 related articles for article (PubMed ID: 16218169)

  • 1. Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis.
    Viganò M; Colombo M; Aroldi A; Lunghi G; Manenti E; Ponticelli C; Lampertico P
    Antivir Ther; 2005; 10(6):709-13. PubMed ID: 16218169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.
    Wong VW; Wong GL; Tsang SW; Hui AY; Chim AM; Yiu KK; Chan HY; Chan FK; Sung JJ; Chan HL
    Antivir Ther; 2008; 13(4):571-9. PubMed ID: 18672536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An open-label study of lamivudine for chronic hepatitis B in six patients with chronic renal failure before and after kidney transplantation.
    Ben-Ari Z; Broida E; Kittai Y; Chagnac A; Tur-Kaspa R
    Am J Gastroenterol; 2000 Dec; 95(12):3579-83. PubMed ID: 11151895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beneficial effects of 'lamivudine pulse' therapy in HBeAg-positive patients with normal ALT*.
    Sarin SK; Sandhu BS; Sharma BC; Jain M; Singh J; Malhotra V
    J Viral Hepat; 2004 Nov; 11(6):552-8. PubMed ID: 15500556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.
    Leung NW; Lai CL; Chang TT; Guan R; Lee CM; Ng KY; Lim SG; Wu PC; Dent JC; Edmundson S; Condreay LD; Chien RN;
    Hepatology; 2001 Jun; 33(6):1527-32. PubMed ID: 11391543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.
    Moskovitz DN; Osiowy C; Giles E; Tomlinson G; Heathcote EJ
    J Viral Hepat; 2005 Jul; 12(4):398-404. PubMed ID: 15985011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of long-term lamivudine in chronic hepatitis B virus-infected children.
    Ozgenç F; Arikan C; Sertoz RY; Nart D; Aydogdu S; Yagci RV
    Antivir Ther; 2004 Oct; 9(5):729-32. PubMed ID: 15535410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: an 8-year follow-up study.
    Akuta N; Suzuki F; Suzuki Y; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
    J Med Virol; 2005 Apr; 75(4):491-8. PubMed ID: 15714490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy.
    Yuen MF; Fung J; Seto WK; Wong DK; Yuen JC; Lai CL
    Antivir Ther; 2009; 14(5):679-85. PubMed ID: 19704171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
    Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
    Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease.
    Yuen MF; Seto WK; Chow DH; Tsui K; Wong DK; Ngai VW; Wong BC; Fung J; Yuen JC; Lai CL
    Antivir Ther; 2007; 12(8):1295-303. PubMed ID: 18240869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A three-month course of lamivudine therapy in HBeAg-positive hepatitis B patients with normal aminotransferase levels.
    Yalçin K; Değertekin H; Kokoğlu OF; Ayaz C
    Turk J Gastroenterol; 2004 Mar; 15(1):14-20. PubMed ID: 15264116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An extended two-year trial of lamivudine in Chinese patients with chronic hepatitis B.
    Yao G; Cui Z; Wang B; Yao J; Zeng M
    Chin Med J (Engl); 2002 Dec; 115(12):1814-8. PubMed ID: 12622930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation.
    Fontana RJ; Hann HW; Wright T; Everson G; Baker A; Schiff ER; Riely C; Anschuetz G; Riker-Hopkins M; Brown N;
    Liver Transpl; 2001 Jun; 7(6):504-10. PubMed ID: 11443577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multi-center open study to determine the effect of lamivudine on HBV DNA clearance and to assess the safety of the regimen in patients with chronic hepatitis B infection.
    Mazur W; Król F; Cianciara J; Nazzal K; Gładysz A; Juszczyk J; Bolewska B; Adamek J; Czajka B; Swietek K; Kryczka W; Gonciarz Z
    Med Sci Monit; 2002 Apr; 8(4):CR257-62. PubMed ID: 11951067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B.
    Villeneuve JP; Condreay LD; Willems B; Pomier-Layrargues G; Fenyves D; Bilodeau M; Leduc R; Peltekian K; Wong F; Margulies M; Heathcote EJ
    Hepatology; 2000 Jan; 31(1):207-10. PubMed ID: 10613747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lamivudine as initial treatment for chronic hepatitis B in the United States.
    Dienstag JL; Schiff ER; Wright TL; Perrillo RP; Hann HW; Goodman Z; Crowther L; Condreay LD; Woessner M; Rubin M; Brown NA
    N Engl J Med; 1999 Oct; 341(17):1256-63. PubMed ID: 10528035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors influencing outcome of lamivudine in anti-HBe-positive chronic hepatitis B.
    Ascione A; Ascione T; Lanza AG; Utech W; Di Costanzo GG; Macri M
    Hepatogastroenterology; 2006; 53(72):919-23. PubMed ID: 17153453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.
    Lai CL; Rosmawati M; Lao J; Van Vlierberghe H; Anderson FH; Thomas N; Dehertogh D
    Gastroenterology; 2002 Dec; 123(6):1831-8. PubMed ID: 12454840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy.
    Suzuki F; Tsubota A; Akuta N; Someya T; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Miyakawa Y; Kumada H
    J Gastroenterol; 2002; 37(11):922-7. PubMed ID: 12483247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.